9 completed, 2 terminated. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow Growth Hormone Deficiency: new trials by email Literature Review of Growth Hormone Deficiency trials Research Report on Growth Hormone Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects somapacitan - Healthy Volunteers, Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 33 | 2019-03-29 | 2019-08-06 |
| Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers MOD-4023, Placebo - Growth Hormone Deficiency | Phase 1 | Completed | OPKO Health, Inc. | 42 | 2015-01-01 | 2019-09-30 |
| Phase 1 Safety Study of ALRN-5281 in Healthy Subjects ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg - Growth Hormone Deficiency | Phase 1 | Completed | Aileron Therapeutics, Inc. | 33 | 2013-01-01 | 2013-05-30 |
| Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Somatropin, Placebo - Growth Hormone Deficiency | Phase 1 | Completed | HanAll BioPharma Co., Ltd. | 40 | 2011-09-01 | 2012-10-16 |
| Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg - Obesity, Short Stature | Phase 1 / Phase 2 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 37 | 2011-07-01 | 2018-12-17 |
| VRS-317 in Adult Subjects With Growth Hormone Deficiency VRS-317 - Growth Hormone Deficiency | Phase 1 | Completed | Versartis Inc. | 50 | 2011-03-01 | 2012-07-23 |
| Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children somatropin AQ, pegylated somatropin - Growth Hormone Deficiency | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 12 | 2010-03-01 | 2012-06-14 |
| r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial r-hGH liquid (Saizen), r-hGH freeze-dried - Growth Failure, Growth Hormone Deficiency | Phase 1 | Completed | EMD Serono | 30 | 2008-07-01 | 2013-10-23 |
| Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors Recombinant Human Growth Hormone, Recombinant Human IGF-1 - Growth Hormone Deficiency | Phase 1 / Phase 2 | Terminated | Columbia University | 5 | 2008-01-01 | 2024-07-17 |
| A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency hGH-ViaDerm™ System (hGH or somatropin), hGH-ViaDerm™ System - Growth Hormone Deficiency | Phase 1 | Completed | Teva Neuroscience, Inc. | 60 | 2007-04-01 | 2013-09-02 |
| Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency Syntropin - Growth Hormone Deficiency | Phase 1 | Completed | Phage Pharmaceuticals, Inc. | 20 | 2004-08-01 | 2012-03-12 |
Dwarfism, Pituitary (11) · Dwarfism (2) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Bone Diseases, Endocrine (1) · Brain Diseases (1) · Failure to Thrive (1) · Hypopituitarism (1) · Musculoskeletal Diseases (1) · Obesity (1) · Overweight (1) · Pituitary Diseases (1)
Central Nervous System Diseases (11) · Endocrine System Diseases (11) · Hypothalamic Diseases (11) · Nervous System Diseases (11) · Bone Diseases (10) · Bone Diseases, Developmental (10) · Bone Diseases, Endocrine (10) · Brain Diseases (10) · Hypopituitarism (10) · Musculoskeletal Diseases (10) · Pituitary Diseases (10) · Dwarfism (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Pathological Conditions, Signs and Symptoms (2)
Human Growth Hormone (4) · Growth Hormone (1) · Growth Hormone-Releasing Hormone (1) · Growth and Development (1) · Hormone Replacement Therapy (1) · Hormones (1) · Hormones, Hormone Substitutes, and Hormone Antagonists (1) · Insulin-Like Growth Factor Binding Protein 3 (1) · Insulin-Like Growth Factor I (1) · MOD-4023 (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) (1) · Pharmacokinetics (1) · somapacitan (1)
Aileron Therapeutics, Inc. (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · EMD Serono (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · HanAll BioPharma Co., Ltd. (1) · Novo Nordisk A/S (1) · OPKO Health, Inc. (1) · Phage Pharmaceuticals, Inc. (1) · Teva Neuroscience, Inc. (1) · Versartis Inc. (1)
United States (6) · Germany (2) · South Korea (1)
Bradley D Vince, D.O. (1) · Hubert C Chen, M.D. (1) · Jack A Yanovski, M.D. (1) · Kyung-Sang Yu, Medicine (1) · Luo Xiaoping, Doctor (1) · Mark Kipnes, MD (1) · Michael Lissy, MD (1) · Noa Avisar, PhD (1) · Pamela U. Freda, M.D. (1)
PMID 20961422, PMID 23585663, PMID 38969919
2018 (1)